Search

Displaying results 4321 - 4330 of 7063 in total
  1. Drug

    Idraparinux

    go.drugbank.com/drugs/DB06406
    Investigational

    As a result, Sanofi stopped the development of the drug. … Idraparinux, a synthetic pentasaccharide is an antithrombin-dependent inhibitor of activated factor X. It was developed for the treatment and prevention of thromboembolic events.

    Categories: Factor Xa Inhibitors
  2. Drug

    Cellspan Esophageal Implant

    go.drugbank.com/drugs/DB18688
    Experimental

    The Cellspan Esophageal ImplantTM (CEI) composes of autologous adipose-derived mesenchymal stromal cells (Ad-MSC) seeded onto a polyurethane tubular mesh cell delivery device.

  3. Drug

    Palladium Pd-103

    go.drugbank.com/drugs/DB15016
    Experimental

    Palladium Pd-103 is under investigation in clinical trial NCT00247312 (Pd-103 Dose De-Escalation for Early Stage Prostate Cancer: A Prospective Randomized Trial).

  4. Drug

    Nabilone

    go.drugbank.com/drugs/DB00486
    ApprovedInvestigational

    From a pharmacological perspective, Cannabis' diverse receptor profile explains its potential application for such a wide variety of medical conditions. … Nabilone is a racemate consisting of the (S,S) and the (R,R) isomers.

  5. Drug

    Sofosbuvir

    go.drugbank.com/drugs/DB08934
    ApprovedInvestigational

    As a prodrug nucleotide analog, Sofosbuvir is metabolized into its active form as the antiviral agent 2'-deoxy-2'-α-fluoro-β-C-methyluridine-5'-triphosphate (also known as GS-461203), which acts as a defective … Approved in October 2014 by the FDA, Harvoni is indicated for the treatment of HCV genotypes 1, 4, 5, and 6 with or without [DB00811] depending on the level of liver damage or cirrhosis [FDA Label].

  6. Drug

    TERT-572

    go.drugbank.com/drugs/DB17286
    Investigational

    Categories: DNA-Directed DNA Polymerase, DNA Nucleotidyltransferases
  7. Drug

    Nedosiran

    go.drugbank.com/drugs/DB17635
    ApprovedInvestigational

    [A261685] Nedosiran was approved by the FDA on October 2<sup>nd</sup>, 2023, under the brand name RIVFLOZA to lower urinary oxalate levels in children 9 years of age and older and adults with primary

  8. Drug

    Acipimox

    go.drugbank.com/drugs/DB09055
    ApprovedInvestigational

    Acipimox is a niacin derivative used as a hypolipidemic agent. … Adverse effects include flushing (associated with Prostaglandin D2), palpitations, and GI disturbances. Flushing can be reduced by taking aspirin 20-30 min before taking Acipimox.

  9. Drug

    Glycyrrhizic acid

    go.drugbank.com/drugs/DB13751
    ApprovedInvestigational

    [F79] It is a triterpene glycoside with glycyrrhetinic acid that possesses a wide range of pharmacological and biological activities. … [T204] Glycyrrhizic acid has been developed in Japan and China as a hepatoprotective drug in cases of chronic hepatitis.

  10. Drug

    Otilimab

    go.drugbank.com/drugs/DB06303
    Investigational

    Investigated for the treatment of osteoarthritis and rheumatoid arthritis (RA).